124 related articles for article (PubMed ID: 15686508)
1. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
Dilek I; Ayakta H; Demir C; Meral C; Ozturk M
Clin Lab Haematol; 2005 Feb; 27(1):51-5. PubMed ID: 15686508
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
3. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 125 levels in children with non-Hodgkin's lymphoma.
Kutluk T; Varan A; Erbaş B; Büyükpamukçu M
Pediatr Hematol Oncol; 1999; 16(4):311-9. PubMed ID: 10407867
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 125 levels in patients with chronic lymphocytic leukemia.
Bairey O; Shaklai M
Clin Lab Haematol; 2005 Feb; 27(1):57-60. PubMed ID: 15686509
[TBL] [Abstract][Full Text] [Related]
6. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
7. Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome.
Pamuk GE; Turgut B; Demir M; Vural O
J Exp Clin Cancer Res; 2006 Dec; 25(4):537-41. PubMed ID: 17310845
[TBL] [Abstract][Full Text] [Related]
8. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
[TBL] [Abstract][Full Text] [Related]
9. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics.
Pamuk GE; Demir M; Harmandar F; Yesil Y; Turgut B; Vural O
Exp Oncol; 2006 Sep; 28(3):241-4. PubMed ID: 17080020
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
12. Family history of hematopoietic malignancy and risk of lymphoma.
Chang ET; Smedby KE; Hjalgrim H; Porwit-MacDonald A; Roos G; Glimelius B; Adami HO
J Natl Cancer Inst; 2005 Oct; 97(19):1466-74. PubMed ID: 16204696
[TBL] [Abstract][Full Text] [Related]
13. [Study on serum erythropoietin levels in patients with hematologic malignancies].
Han B; Shi YK; Zhu J; He XH; Lin NJ; Li SL; Shen T
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):543-5. PubMed ID: 17172129
[TBL] [Abstract][Full Text] [Related]
14. [Utility of the copper/zinc ratio in patients with lymphoma or acute or chronic leukemias].
Rosas R; Poo JL; Montemayor A; Isoard F; Majluf A; Labardini J
Rev Invest Clin; 1995; 47(6):447-52. PubMed ID: 8850142
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
17. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005.
Pulte D; Gondos A; Brenner H
Cancer; 2009 Nov; 115(21):4973-9. PubMed ID: 19705347
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
[TBL] [Abstract][Full Text] [Related]
19. CA 125 elevations in patients with malignant lymphomas.
Fehm T; Beck E; Valerius T; Gramatzki M; Jäger W
Tumour Biol; 1998; 19(4):283-9. PubMed ID: 9679739
[TBL] [Abstract][Full Text] [Related]
20. Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?
Pamuk GE; Uyanik MS; Pamuk ON; Maden M; Tapan U
Hematology; 2015 Jun; 20(5):267-71. PubMed ID: 25271869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
